Company intelligence / Profile preview
Chimeron Bio
Philadelphia, Pennsylvania, United Stateschimeron.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Chimeron Bio's programs are at pre-clinical or discovery stage, advancing a platform of self-amplifying RNA and nanoparticle technologies for enhanced gene expression, with early data supporting robust in vivo CAR-T, immuno-oncology, and vaccine potentials.
- Therapeutic areas
- OncologyInfectious DiseasesRare Diseases
- Modalities
- Self-amplifying RNAmRNA-based drugsSmall moleculesiRNAVaccineNanoparticle
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
FUJIFILM Diosynth Biotechnologies
Beyond the preview
Go deeper on Chimeron Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chimeron Bio.